A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
Open Access
- 14 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 70 (6), 1667-1678
- https://doi.org/10.1007/s00262-020-02810-6
Abstract
Background It is still unclear how to combine biomarkers to identify patients who will truly benefit from anti-PD-1 agents in NSCLC. This study investigates exosomal mRNA expression of PD-L1 and IFN-γ, PD-L1 polymorphisms, tumor mutational load (TML) in circulating cell-free DNA (cfDNA) and radiomic features as possible predictive markers of response to nivolumab and pembrolizumab in metastatic NSCLC patients. Methods Patients were enrolled and blood (12 ml) was collected at baseline before receiving anti-PD-1 therapy. Exosome-derived mRNA and cfDNA were extracted to analyse PD-L1 and IFN-γ expression and tumor mutational load (TML) by digital droplet PCR (ddPCR) and next-generation sequencing (NGS), respectively. The PD-L1 single nucleotide polymorphisms (SNPs) c.-14-368 T > C and c.*395G > C, were analysed on genomic DNA by Real-Time PCR. A radiomic analysis was performed on the QUIBIM Precision® V3.0 platform. Results Thirty-eight patients were enrolled. High baseline IFN-γ was independently associated with shorter median PFS (5.6 months vs. not reached p = 0.0057), and levels of PD-L1 showed an increase at 3 months vs. baseline in patients who progressed (p = 0.01). PD-L1 baseline levels showed significant direct and inverse relationships with radiomic features. Radiomic features also inversely correlated with PD-L1 expression in tumor tissue. In subjects receiving nivolumab, median PFS was shorter in carriers of c.*395GG vs. c.*395GC/CC genotype (2.3 months vs. not reached, p = 0.041). Lastly, responders had higher non-synonymous mutations and more links between co-occurring genetic somatic mutations and ARID1A alterations as well. Conclusions A combined multiparametric approach may provide a better understanding of the molecular determinants of response to immunotherapy.Keywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017, grant n. 2017NR7W5K)
- Università di Pisa
This publication has 70 references indexed in Scilit:
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Biogenesis and secretion of exosomesCurrent Opinion in Cell Biology, 2014
- Robust Radiomics Feature Quantification Using Semiautomatic Volumetric SegmentationPLOS ONE, 2014
- The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of MeasurementClinical Cancer Research, 2013
- Radiomics: the process and the challengesMagnetic Resonance Imaging, 2012
- Tumor cell-derived exosomes: A message in a bottleBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2012
- Multi-stage Learning for Robust Lung Segmentation in Challenging CT VolumesLecture Notes in Computer Science, 2011
- Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung CancerClinical Cancer Research, 2008
- Regulation of Interferon‐γ During Innate and Adaptive Immune ResponsesAdvances in Immunology, 2007
- Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish populationMutation research. Reviews in mutation research, 2006